title: Adiponectin inhibits VEGF-A in prostate cancer cells.
abstract: A role of adiponectin in tumorigenesis has recently been appreciated. Although plasma adiponectin levels in subjects with prostate cancer have been found to be significantly lower than in subjects with benign prostatic hyperplasia or in normal healthy controls, the underlying molecular mechanisms remain unknown. Here, we not only detected significant decreases in plasma adiponectin levels in prostate cancer patients, but also showed significant decreases in adiponectin receptor I (AdipoR1) levels in the resected prostate cancer specimen. Prostate cancer cell lines examined in the current study had all lower levels of adiponectin and AdipoR1, compared to normal healthy prostate tissue. Moreover, overexpression of adiponectin in prostate cancer cells decreased production of vascular endothelial growth factor A (VEGF-A), while adiponectin depletion increased VEGF-A. Furthermore, adiponectin seemed to activate AMPK/TSC2 to inhibit mTor-mediated activation of VEGF-A. Taken together, our data suggest that adiponectin may play an essential role in suppressing growth of prostate cancer cells through inhibition of VEGF-A-mediated cancer neovascularization.
authors.affiliation: Department of Urology, Shanghai 10th People's Hospital, Tongji University School of Medicine, 301 Yanchangzhong Road, Shanghai, 200072, China.
authors.forename: Qiruo
authors.initials: Q
authors.lastname: Gao
authors.forename: Junhua
authors.initials: J
authors.lastname: Zheng
authors.forename: Xudong
authors.initials: X
authors.lastname: Yao
authors.forename: Bo
authors.initials: B
authors.lastname: Peng
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000235:genetics / Q000378:metabolism; D052242:Adiponectin / Q000096:biosynthesis / Q000097:blood*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000235:genetics; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D008297:Male; D009389:Neovascularization, Pathologic / Q000097:blood / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000097:blood* / Q000473:pathology; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology; D054419:Receptors, Adiponectin / Q000096:biosynthesis / Q000097:blood*; D058570:TOR Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism; D000077005:Tuberous Sclerosis Complex 2 Protein; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis* / Q000235:genetics
chemical_list: C475418:ADIPOR1 protein, human; D052242:Adiponectin; D054419:Receptors, Adiponectin; C000624653:TSC2 protein, human; D000077005:Tuberous Sclerosis Complex 2 Protein; D025521:Tumor Suppressor Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D055372:AMP-Activated Protein Kinases